Loading...
•
Dec 31, 2023
Amicus Therapeutics Q4 2023 Earnings Report
Amicus Therapeutics reported Q4 2023 financial results, achieving non-GAAP profitability and experiencing strong patient demand for Galafold and Pombiliti + Opfolda.
Key Takeaways
Amicus Therapeutics announced full-year 2023 financial results, with total revenue of $399.4 million, a 21% increase year-over-year. The company achieved non-GAAP profitability in Q4 and anticipates full-year non-GAAP profitability in 2024.
Amicus strengthened its leadership position in Fabry and Pompe disease globally.
The company achieved its goal of non-GAAP profitability in the fourth quarter.
Patient demand for Galafold exceeded expectations and grew at the highest rate in four years.
Pombiliti + Opfolda was successfully launched in the three largest Pompe disease markets.
Amicus Therapeutics
Amicus Therapeutics
Forward Guidance
Amicus Therapeutics projects 2024 Galafold revenue growth of 11-16% at CER and anticipates full-year non-GAAP profitability in 2024.
Positive Outlook
- Continued Galafold growth
- Successful Pombiliti + Opfolda launches
- Sustained double-digit Galafold performance
- Ongoing global commercial launch of Pombiliti + Opfolda
- First full year of non-GAAP profitability